CA3108719A1 - Procede et systeme permettant d'identifier des individus a haut risque de maladie inflammatoire intestinale, et methode de traitement - Google Patents

Procede et systeme permettant d'identifier des individus a haut risque de maladie inflammatoire intestinale, et methode de traitement Download PDF

Info

Publication number
CA3108719A1
CA3108719A1 CA3108719A CA3108719A CA3108719A1 CA 3108719 A1 CA3108719 A1 CA 3108719A1 CA 3108719 A CA3108719 A CA 3108719A CA 3108719 A CA3108719 A CA 3108719A CA 3108719 A1 CA3108719 A1 CA 3108719A1
Authority
CA
Canada
Prior art keywords
risk
developing
individual
determining
value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3108719A
Other languages
English (en)
Inventor
Bruce R. Yacyshyn
Mary E. YACYSHYN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3108719A1 publication Critical patent/CA3108719A1/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medicinal Chemistry (AREA)
  • Data Mining & Analysis (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)

Abstract

L'invention concerne une méthode et un système destinés à un protocole de traitement plus efficace et personnalisé, basé sur des biomarqueurs cibles à valeur prédictive identifiés cliniquement qui sont associés à la prédiction du risque pour un individu de développer une MICI, et comprenant un ou plusieurs panels prédictifs de biomarqueurs cibles à valeur prédictive qui sont utilisés pour déterminer le risque pour un individu de développer une MICI, afin de déterminer si un traitement doit être administré pour diminuer le risque, et de plus permettant de déterminer l'efficacité qu'aurait un traitement de l'individu par de la mésalamine et d'identifier et de valider de façon efficace de nouvelles cibles de médicament pour de nouveaux agents thérapeutiques contre les MICI, et de nouvelles normes diagnostiques et de nouveaux standards diagnostiques pour des stratégies thérapeutiques contre les MICI.
CA3108719A 2018-08-21 2019-08-20 Procede et systeme permettant d'identifier des individus a haut risque de maladie inflammatoire intestinale, et methode de traitement Pending CA3108719A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862720468P 2018-08-21 2018-08-21
US62/720,468 2018-08-21
PCT/US2019/047231 WO2020041287A1 (fr) 2018-08-21 2019-08-20 Procédé et système permettant d'identifier des individus à haut risque de maladie inflammatoire intestinale, et méthode de traitement

Publications (1)

Publication Number Publication Date
CA3108719A1 true CA3108719A1 (fr) 2020-02-27

Family

ID=69591310

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3108719A Pending CA3108719A1 (fr) 2018-08-21 2019-08-20 Procede et systeme permettant d'identifier des individus a haut risque de maladie inflammatoire intestinale, et methode de traitement

Country Status (4)

Country Link
EP (1) EP3840831A4 (fr)
AU (1) AU2019325238A1 (fr)
CA (1) CA3108719A1 (fr)
WO (1) WO2020041287A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833720B2 (en) * 2008-03-14 2010-11-16 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome
US20120171672A1 (en) 2009-04-14 2012-07-05 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
EP2419529B1 (fr) * 2009-04-14 2015-05-20 Nestec S.A. Pronostics des maladies inflammatoires de l'intestin
US20130303391A1 (en) * 2010-09-14 2013-11-14 Oklahoma Medical Research Foundation Methods for diagnosis and prognosis of inflammatory bowel disease using cytokine profiles
WO2013059732A1 (fr) * 2011-10-21 2013-04-25 Nestec S.A. Procédés pour l'amélioration du diagnostic d'une maladie intestinale inflammatoire
WO2014182689A1 (fr) * 2013-05-06 2014-11-13 Yacyshyn Bruce R Procédé d'utilisation de biomarqueurs pour prédire une maladie intestinale inflammatoire
US10295527B2 (en) * 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis

Also Published As

Publication number Publication date
EP3840831A4 (fr) 2022-05-11
WO2020041287A1 (fr) 2020-02-27
EP3840831A1 (fr) 2021-06-30
AU2019325238A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
Floege et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Murillo Perez et al. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response
Cortellini et al. Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression≥ 50% and their relationship with clinical outcomes
Neuschwander‐Tetri et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease
van Dongen et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double‐blind, randomized, placebo‐controlled trial
Sanders et al. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?
Quarneti et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis
Barsam et al. The impact of body weight on rivaroxaban pharmacokinetics
Shah et al. Protective effect against cancer of antibodies to the large subunits of both RNA polymerases I and III in scleroderma
Astorri et al. Towards a stratified targeted approach with biologic treatments in rheumatoid arthritis: role of synovial pathobiology
Bodini et al. Comparison of two different techniques to assess adalimumab trough levels in patients with Crohn’s disease
Casteele et al. Development and validation of a clinical decision support tool that incorporates pharmacokinetic data to predict endoscopic healing in patients treated with infliximab
Siddiqui et al. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
Macaluso et al. A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease
Zhou et al. The clinical value of hematological markers in rheumatoid arthritis patients treated with tocilizumab
Ruscitti et al. Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literature
Kitsioulis et al. Effectiveness of autologous whole-blood injections in patients with refractory chronic spontaneous urticaria
Netterberg et al. The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin‐6 and C‐reactive protein by modelling
CA3108719A1 (fr) Procede et systeme permettant d'identifier des individus a haut risque de maladie inflammatoire intestinale, et methode de traitement
Karakasis et al. Accelerated atherosclerosis and management of cardiovascular risk in autoimmune rheumatic diseases: an updated review
Keller et al. Higher Molecular Injury at Diagnosis of Acute Cellular Rejection Increases the Risk of Lung Allograft Failure: A Clinical Trial.
Kitas et al. The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial
Corominas et al. Rheumatoid arthritis: defining clinical and ultrasound deep remission
De Nicola et al. Hypertension management in chronic kidney disease: translating guidelines into daily practice
Kim et al. Do Hyun Kim,“